FDA Shakeup Continues As Two Key Officials Ousted

The FDA experienced a shake-up with the departure of Nicole Verdun and Rachael Anatol, the top two officials overseeing cell and gene therapy reviews, leading to uncertainty in the sector. This follows the earlier resignation of CBER director Peter Marks amid disagreements with the new health secretary, Robert F. Kennedy Jr., and the appointment of Vinay Prasad, who has previously criticized some gene therapy approvals. Gene therapy stocks like Crispr Therapeutics and Sarepta Therapeutics saw declines, with the latter potentially facing increased scrutiny due to Verdun's reported concerns over its Duchenne muscular dystrophy drug, Elevidys.

Analysis

A significant leadership shake-up at the FDA's Office of Therapeutic Products (OTP) has introduced considerable uncertainty for the cell and gene therapy sector. The ousting of director Nicole Verdun and her deputy, Rachael Anatol, follows the recent appointment of Vinay Prasad as the new head of the Center for Biologics Evaluation and Research (CBER). This transition, stemming from the resignation of former CBER director Peter Marks over disagreements with the new health administration, signals a potential shift in regulatory philosophy. The market reacted negatively, with gene therapy stocks like Sarepta Therapeutics (SRPT) falling 3.3% and Crispr Therapeutics (CRSP) declining 0.4%. The situation poses a particular risk for Sarepta, as Verdun reportedly opposed the initial approval of its Duchenne muscular dystrophy drug, Elevidys, an approval that was ultimately pushed through by the now-departed Marks and has been criticized by Prasad. While some analysts suggest that support for rare disease therapies will continue, the departures create ambiguity about future regulatory standards, especially concerning controversial approvals and the regulation of products like CAR-T therapies.

Key Decisions for Investors

• Investors should brace for heightened volatility and regulatory headline risk across the cell and gene therapy space due to the leadership overhaul at the FDA's CBER.
• Holders of Sarepta Therapeutics (SRPT) face elevated risk, as the new CBER leadership has been critical of its drug Elevidys, and should closely monitor any forthcoming FDA communications regarding the treatment.
• It is prudent to reassess positions in companies with pending or borderline therapy approvals, as the new regulatory regime under Vinay Prasad may apply more stringent efficacy and safety standards than previously seen.
• Consider favoring companies within the biotech sector that have robust, unambiguous clinical data, as they may be better insulated from the increased regulatory scrutiny and leadership uncertainty.